AP2004003014A0 - Use of specific dose of fondaparinux sodium for the treatment of ACS. - Google Patents

Use of specific dose of fondaparinux sodium for the treatment of ACS.

Info

Publication number
AP2004003014A0
AP2004003014A0 AP2004003014A AP2004003014A AP2004003014A0 AP 2004003014 A0 AP2004003014 A0 AP 2004003014A0 AP 2004003014 A AP2004003014 A AP 2004003014A AP 2004003014 A AP2004003014 A AP 2004003014A AP 2004003014 A0 AP2004003014 A0 AP 2004003014A0
Authority
AP
ARIPO
Prior art keywords
acs
treatment
specific dose
fondaparinux sodium
fondaparinux
Prior art date
Application number
AP2004003014A
Other versions
AP1820A (en
Original Assignee
Sanofi Synthalebo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8181220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2004003014(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Synthalebo filed Critical Sanofi Synthalebo
Publication of AP2004003014A0 publication Critical patent/AP2004003014A0/en
Application granted granted Critical
Publication of AP1820A publication Critical patent/AP1820A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
APAP/P/2004/003014A 2001-11-13 2002-11-07 Use of specific dose of fondaparinux sodium for the treatment of ACS. AP1820A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204323 2001-11-13
PCT/EP2002/012482 WO2003041722A1 (en) 2001-11-13 2002-11-07 Use of specific dose of fondaparinux sodium for the treatment of acs

Publications (2)

Publication Number Publication Date
AP2004003014A0 true AP2004003014A0 (en) 2004-06-30
AP1820A AP1820A (en) 2008-01-11

Family

ID=8181220

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2004/003014A AP1820A (en) 2001-11-13 2002-11-07 Use of specific dose of fondaparinux sodium for the treatment of ACS.

Country Status (37)

Country Link
US (1) US20040248848A1 (en)
EP (1) EP1446131B1 (en)
JP (1) JP4523276B2 (en)
KR (1) KR20050044318A (en)
CN (1) CN1602197A (en)
AP (1) AP1820A (en)
AR (1) AR037291A1 (en)
AT (1) ATE361753T1 (en)
AU (1) AU2002351915B2 (en)
BR (1) BR0212915A (en)
CA (1) CA2465776A1 (en)
CO (1) CO5580790A2 (en)
CY (1) CY1106765T1 (en)
DE (1) DE60220084T2 (en)
DK (1) DK1446131T3 (en)
EA (1) EA007325B1 (en)
EC (1) ECSP045041A (en)
ES (1) ES2287343T3 (en)
GE (1) GEP20074097B (en)
HK (1) HK1070561A1 (en)
HR (1) HRP20040303B1 (en)
HU (1) HU228959B1 (en)
IL (2) IL161114A0 (en)
IS (1) IS2484B (en)
MA (1) MA27071A1 (en)
ME (2) ME00229B (en)
MX (1) MXPA04003045A (en)
NO (1) NO20041320L (en)
NZ (1) NZ552129A (en)
PE (1) PE20030740A1 (en)
PL (1) PL206008B1 (en)
PT (1) PT1446131E (en)
RS (1) RS50906B (en)
SI (1) SI1446131T1 (en)
UA (1) UA80399C2 (en)
WO (1) WO2003041722A1 (en)
ZA (1) ZA200402464B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075910A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched fondaparinux
BR112017020091A2 (en) * 2015-03-20 2018-11-06 Aarhus Universitet pcsk9 inhibitors for treatment of lipoprotein metabolism disorders
US10688249B2 (en) * 2015-06-11 2020-06-23 Virchow Biotech Pvt. Ltd. Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same
CN107595769A (en) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 A kind of preparation method of Fondaparinux sodium injecta composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (en) * 1990-05-23 1991-11-29 Midy Spa N-SUBSTITUTED TRIFLUOROMETHYLPHENYLTETRAHYDROPYRIDINES PROCESS FOR THEIR PREPARATION, INTERMEDIATES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
CA2199642C (en) * 1997-03-10 2001-05-08 Roger Cariou Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin
FR2764511B1 (en) * 1997-06-13 2000-09-08 Sanofi Sa COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF ARTERIAL THROMBOSIS AND USE OF A FACTOR XA INHIBITOR ALONE AND / OR IN COMBINATION WITH A PLAQUET ANTIAGGREGANT
US20040087543A1 (en) * 2002-04-25 2004-05-06 Zachary Shriver Methods and products for mucosal delivery

Also Published As

Publication number Publication date
ZA200402464B (en) 2005-06-29
AU2002351915B2 (en) 2007-11-29
PT1446131E (en) 2007-08-07
BR0212915A (en) 2004-10-13
DK1446131T3 (en) 2007-09-10
ME00229B (en) 2011-10-10
HU228959B1 (en) 2013-07-29
HRP20040303A2 (en) 2004-10-31
US20040248848A1 (en) 2004-12-09
MXPA04003045A (en) 2005-06-20
HK1070561A1 (en) 2005-06-24
DE60220084D1 (en) 2007-06-21
MA27071A1 (en) 2004-12-20
IL161114A0 (en) 2004-08-31
MEP1108A (en) 2011-02-10
RS26704A (en) 2007-02-05
KR20050044318A (en) 2005-05-12
CA2465776A1 (en) 2003-05-22
CO5580790A2 (en) 2005-11-30
AP1820A (en) 2008-01-11
EA007325B1 (en) 2006-08-25
GEP20074097B (en) 2007-05-10
JP2005509007A (en) 2005-04-07
EP1446131B1 (en) 2007-05-09
DE60220084T2 (en) 2008-01-10
HUP0401462A2 (en) 2006-02-28
EA200400382A1 (en) 2004-10-28
IS7199A (en) 2004-03-29
RS50906B (en) 2010-08-31
CY1106765T1 (en) 2012-05-23
NZ552129A (en) 2008-04-30
CN1602197A (en) 2005-03-30
HUP0401462A3 (en) 2006-04-28
AR037291A1 (en) 2004-11-03
ES2287343T3 (en) 2007-12-16
IS2484B (en) 2008-12-15
UA80399C2 (en) 2007-09-25
ATE361753T1 (en) 2007-06-15
JP4523276B2 (en) 2010-08-11
EP1446131A1 (en) 2004-08-18
PL369027A1 (en) 2005-04-18
IL161114A (en) 2010-11-30
ECSP045041A (en) 2004-04-28
SI1446131T1 (en) 2007-10-31
PE20030740A1 (en) 2003-08-28
HRP20040303B1 (en) 2012-02-29
NO20041320L (en) 2004-06-14
WO2003041722A1 (en) 2003-05-22
PL206008B1 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
IL196301A0 (en) Medicament for the treatment of hapatitis c
GB2371462B (en) Radiation treatment system
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
HK1072443A1 (en) Immunoconjugates for the treatment of tumours
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
HK1070561A1 (en) Use of specific dose of fandaparinux sodium for the treatment of acs
LT1496918T (en) Use of sodium meta-arsenite for the treatment of tumours
MXPA03006412A (en) Methods of administering epothilone analogs for the treatment of cancer.
MXPA03003032A (en) Combination therapy for the treatment of estrogen-sensitive disease.
ZA200203166B (en) Treatment of cancer.
GB0212790D0 (en) Medicament for the treatment of diabetes
GB0119370D0 (en) Therapeutic agent
ZA200308216B (en) Medicament for the treatment of immuno-deficiency conditions.
GB0106983D0 (en) Medical treatment
GB0127267D0 (en) Medical treatment
GB0127271D0 (en) Medical treatment
GB0128813D0 (en) Medical treatment
GB0118977D0 (en) New medical treatment
ZA200308844B (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.
ZA200304439B (en) Therapeutic treatment.
GB9903558D0 (en) Medical treatment